Dr. Singh Discusses Immunotherapy Study in GIST

Arun S. Singh, MD
Published: Thursday, Jan 25, 2018



Arun S. Singh, MD, Ronald Reagan UCLA Medical Center, discusses the rationale behind a randomized phase II study (NCT02880020) of nivolumab (Opdivo) monotherapy versus nivolumab with ipilimumab (Yervoy) in patients with metastatic or unresectable gastrointestinal stromal tumors (GIST).

GIST is a rare group of tumors that can start anywhere in the gastrointestinal tract. The 2 most common locations are in the stomach and the small intestine. Traditionally, they are treated with surgery but more advanced GISTs are treated with tyrosine kinase inhibitors (TKIs).

Currently, there are 3 drugs that are FDA approved for the treatment of patients with GISTs, including imatinib (Gleevec), sunitinib (Sutent), and regorafenib (Stivarga). However, there are new exciting compounds in clinical trials, says Singh.

The nivolumab combination study is one of the few immunotherapy studies in this space, explains Singh. The trial aims to determine the overall response rate of the combination compared to nivolumab alone.
 


Arun S. Singh, MD, Ronald Reagan UCLA Medical Center, discusses the rationale behind a randomized phase II study (NCT02880020) of nivolumab (Opdivo) monotherapy versus nivolumab with ipilimumab (Yervoy) in patients with metastatic or unresectable gastrointestinal stromal tumors (GIST).

GIST is a rare group of tumors that can start anywhere in the gastrointestinal tract. The 2 most common locations are in the stomach and the small intestine. Traditionally, they are treated with surgery but more advanced GISTs are treated with tyrosine kinase inhibitors (TKIs).

Currently, there are 3 drugs that are FDA approved for the treatment of patients with GISTs, including imatinib (Gleevec), sunitinib (Sutent), and regorafenib (Stivarga). However, there are new exciting compounds in clinical trials, says Singh.

The nivolumab combination study is one of the few immunotherapy studies in this space, explains Singh. The trial aims to determine the overall response rate of the combination compared to nivolumab alone.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x